Encoded Therapeutics, Inc. is a private biotechnology company headquartered in South San Francisco, California, developing gene therapies that use CRISPR-based activation to increase expression of disease-implicated genes for the treatment of severe neurological disorders. The company's lead program, ETX101, uses AAV-mediated CRISPRa to upregulate SCN1A for the treatment of Dravet syndrome[1].
Encoded's platform is built on the insight that many neurological diseases are caused by loss-of-function mutations where one allele is completely non-functional while the other remains intact. Rather than delivering a corrective gene, Encoded uses AAV-delivered CRISPR activation machinery to boost expression of the wild-type allele — essentially amplifying the body's existing backup capacity[2].
This approach contrasts with traditional gene therapy (which delivers a functional copy of the gene) and with ASO approaches (which are non-viral and require repeat dosing). AAV-mediated CRISPRa offers the potential for long-lasting, single-dose treatment with cell-type specificity[?].
Encoded's platform uses AAV-delivered CRISPR activation (CRISPRa) to increase transcription of target genes:
| Factor | Encoded CRISPRa (ETX101) | Stoke TANGO (STK-001) |
|---|---|---|
| Delivery | AAV (one-time) | ASO (repeat dosing) |
| Duration | Potentially lifelong | Requires quarterly dosing |
| Cell targeting | Engineered serotype/promoter | Broad CNS distribution |
| Regulatory precedent | AAV gene therapy precedent | ASO precedent (Spinraza, etc.) |
| Stage | Phase 1 | Phase 2 |
| Immunogenicity risk | AAV antibodies | Minimal |
| Manufacturing | AAV GMP complex | ASO GMP established |
ETX101 is an AAV9-based CRISPR gene activation therapy designed to increase SCN1A expression in inhibitory GABAergic interneurons — the specific cell type where loss of SCN1A causes Dravet syndrome pathophysiology[1:1].
Mechanism:
Clinical Development:
Current Status (March 2026):
Key Differentiator vs. ASOs:
Encoded has indicated pipeline expansion plans targeting:
The company leverages its AAV delivery and CRISPRa platform to address multiple indications where gene upregulation could address the underlying disease[3].
| Round | Amount | Year | Purpose |
|---|---|---|---|
| Series A | $30M | 2019 | Platform development, founding |
| Series B | $70M | 2021 | ETX101 IND-enabling, platform expansion |
| Series C | $135M | 2023 | Phase 1 initiation, manufacturing |
| Series D | $80M | 2025 | ETX101 Phase 1 continuation, manufacturing scale-up |
Total raised: ~$315M (one of the best-funded private gene therapy companies in neurological diseases)
Investors: Top-tier life science investors including RA Capital, Versant Ventures, Foresite Capital, and others[4].
| Metric | Value |
|---|---|
| Status | Private |
| Headquarters | South San Francisco, California |
| Founded | 2019 |
| Total Funding | ~$315M |
| Employees | ~100-150 |
| Valuation | Not publicly disclosed; estimated $500M-1B based on financing rounds |
| Last Round | Series D, $80M (2025) |
Encoded competes in the Dravet syndrome landscape with:
| Competitor | Approach | Stage |
|---|---|---|
| Stoke Therapeutics (STOK) | ASO TANGO (STK-001) | Phase 2, FDA BTD |
| Ultragenyx (GeneTx) | ASO for Angelman | Phase 2 |
| Roche/Neurocrine | AAV gene therapy | IND-enabling |
Competitive advantages:
Competitive risks:
Encoded maintains collaborations with leading neuroscience and gene therapy researchers: